TGTX
Tg Therapeutics·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 6
Bearish signal 0
Consensus Rating "Strong Buy"
Ample Liquidity
High Gross Profit Margin
Significant Net Income Growth
Revenue Beats Expectation
EPS Beats Expectation
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About TGTX
Tg Therapeutics, Inc.
A biopharmaceutical company that develops therapeutics for diseases caused by protien or gene dysfunction
3020 Carrington Mill Blvd, Suite 475, Morrisville, North Carolina 27560
--
TG Therapeutics, Inc., was founded in Delaware in 1993. The company is a fully integrated, commercial-stage biopharmaceutical company focused on the acquisition, development and commercialization of new therapies for B-cell diseases. In addition to a series of studies including several investigational drugs, TG has received BRIUMVI (ublituximab-xiiy) approval from the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with recurrent multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease.
Earnings Call
Q1/2025
Estimate EPS0.17
Actual EPS0.03
Estimate Revenue117.86M
Actual Revenue119.70M
TG Therapeutics Q1 2025: Navigating Contradictions in Subcutaneous Trials, Gross-to-Net Dynamics, and Market Share Growth
May 05,2025 11:12
Earnings Decrypt
Earnings Decrypt
Q2/2025
Estimate EPS0.29
Actual EPS0.17
Estimate Revenue146.27M
Actual Revenue141.10M
TG Therapeutics Q2 2025: Unpacking Contradictions in Market Share, Subcutaneous Trials, and Payer Demand Trends
Aug 04,2025 10:24
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
TGTX has released its 2025 Q3 earnings. EPS was reported at 2.43, versus the expected 0.21, beating expectations. The chart below visualizes how TGTX has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
TGTX has released its 2025 Q3 earnings report, with revenue of 161.71M, reflecting a YoY change of 92.79%, and net profit of 390.89M, showing a YoY change of 9974.61%. The Sankey diagram below clearly presents TGTX's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
